Vizsgálati helyszín
Unite De Recherche Clinique HIA Begin
Saint-Mande, 94160, FranciaországMég nincs intézményhez kötve
- 15futó vizsgálat
- 13lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 29 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis22 vizsgálat
- 2. fázis6 vizsgálat
- 1/2. fázis1 vizsgálat
- Állapot
- Lezárult13 vizsgálat
- Fut, nem toboroz7 vizsgálat
- Toboroz7 vizsgálat
- Még nem toboroz1 vizsgálat
- Felfüggesztve1 vizsgálat
- Fő szponzor
- UNICANCER4 vizsgálat
- Hoffmann-La Roche3 vizsgálat
- Institut Gustave Roussy2 vizsgálat
- Merck Sharp & Dohme LLC2 vizsgálat
- ACELYRIN Inc.1 vizsgálat
- és még 17
Futó vizsgálatok
Toboroz
A clinical trial to provide continued access to remibrutinib (LOU064) for people who are benefiting from it in a previous remibrutinib trial
2025-524078-40-00· 3. fázis· Novartis Pharma AG· Forrás
Még nem toboroz
Multicenter, randomized, double-blinded, placebo-controlled phase 3 trial to evaluate nonavalent HPV vaccine as a secondary prevention in patients treated for human papilloma virus related high-grade squamous intraepithelial lesions.(BioHPV)
2024-520140-42-00· 3. fázis· Institut Gustave Roussy· Forrás
Toboroz
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT07225569· 2. fázis· Sanofi· Forrás
Toboroz
Systemic antitumor treatment with or without pressurized intraperitoneal aerosol chemotherapy (PIPAC) for colon peritoneal metastases – a multicentre phase II randomized trial (PIPOX02)
2024-514560-10-00· 2. fázis· Institut De Cancerologie De L Ouest· Forrás
Toboroz
CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
2023-503317-29-00· 3. fázis· Institut Gustave Roussy· Forrás
Fut, nem toboroz
An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
NCT05513001· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
NCT05170204· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
NCT04916613· 3. fázis· UNICANCER· Forrás
Fut, nem toboroz
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
NCT04497844· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy
NCT03977194· 3. fázis· Intergroupe Francophone de Cancerologie Thoracique· Forrás
Toboroz
Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer
NCT03819101· 3. fázis· Gustave Roussy, Cancer Campus, Grand Paris· Forrás
Fut, nem toboroz
Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients
NCT03799835· 3. fázis· UNICANCER· Forrás
Toboroz
Renal Adjuvant MultiPle Arm Randomised Trial
NCT03288532· 3. fázis· University College, London· Forrás
Fut, nem toboroz
A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse
NCT01952223· 3. fázis· UNICANCER· Forrás
Fut, nem toboroz
Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment
NCT01376752· 3. fázis· UNICANCER· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered in participants with PD-L1 ≥ 1% TC Stage IIB, IIIA, or select IIIB (T3N2 only) NSCLC following resection and adjuvant platinum-based chemotherapy
2023-506696-10-00· 3. fázis· F. Hoffmann-La Roche AG· Forrás
Leállították
Hidradenitis Suppurativa Study of Izokibep
NCT05905783· 3. fázis· ACELYRIN Inc.· Forrás
Fut, nem toboroz
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT05348577· 3. fázis· AstraZeneca· Forrás
Lezárult
Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer
NCT05117242· 2. fázis· Genmab A/S· Forrás
Lezárult
A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer
NCT04746924· 3. fázis· Beigene Ltd.· Forrás
Lezárult
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
NCT04623775· 2. fázis· Bristol-Myers Squibb· Forrás
Lezárult
A Phase 1, Open-Label, Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Patients with Advanced Solid Tumors and Subsequent Expansion Cohorts
2024-518506-41-00· 1/2. fázis· Promontory Therapeutics Inc.· Forrás
Lezárult
Phase II multicenter randomized trial evaluating the association of PIPAC and systemic
chemotherapy versus systemic chemotherapy alone as 1st-line treatment of Malignant
Peritoneal Mesothelioma
NCT03875144· 2. fázis· Institut Regional Du Cancer De Montpellier· Forrás
Lezárult
A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)
NCT03976362· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Lezárult
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
NCT03976323· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Lezárult
A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)
NCT03456063· 3. fázis· Hoffmann-La Roche· Forrás
Lezárult
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
NCT02486718· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
NCT02319837· 3. fázis· Pfizer· Forrás
Hibát jelzek